MedTrace Logo

Cutaneous Lupus Erythematosus and Elidel

NCT00222183 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-06-28

No results posted yet for this study

Summary

This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).

Conditions

  • Lupus Erythematosus, Cutaneous
  • Lupus Erythematosus, Discoid

Interventions

DRUG

Elidel (pimecrolimus)

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Michael Sticherling, Prof. Dr. med. · University of Leipzig, Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222183 on ClinicalTrials.gov